Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole.
about
Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsHistoplasmosis: a clinical and laboratory updateAntigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS.Glycosylation and immunoreactivity of the Histoplasma capsulatum Cfp4 yeast-phase exoantigenClinical use of anti-TNF therapy and increased risk of infectionsManagement of histoplasmosis.Evaluation of an enzyme-linked immunosorbent assay using purified, deglycosylated histoplasmin for different clinical manifestations of histoplasmosis.Detection of histoplasma antigen by a quantitative enzyme immunoassayComparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.Improvements in diagnosis of histoplasmosis.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Diagnosing invasive fungal disease in critically ill patients.Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review.An unusual cause of fever in a patient with common variable immunodeficiency.Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.Antigen Concentrations as an Indicator of Clinical Remission and Disease Relapse in Cats with Histoplasmosis.Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate.Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassayHistoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors.New agents for the treatment of systemic fungal infections--current status.
P2860
Q24239978-CCE5E888-97B9-49BB-BAD7-966B7E764870Q24675642-AD464DE3-387C-4B71-8CD3-3F1E82863DDAQ34104766-699133C2-2DC9-4C0D-90BB-0F2AFFB29663Q34298551-BE15CF9B-ACD0-4F8B-AE51-06F385288BC6Q34338096-7CF7F287-6DAF-41A0-8448-DF1AB585EE0BQ34768480-EE1291CD-4444-42DC-9B0E-B296DC9D2B87Q35052562-AAD2C983-919C-4AC8-BE19-A9EB58334035Q36314106-8383CE95-9A91-4C6E-929C-4B9A02EFD03EQ36422661-4ECA7E6C-9F78-4F10-8B9A-10EBAE96C008Q36627264-D2093206-1475-4014-881C-D367FF753E42Q36868273-D49484A4-F826-4A71-8617-5E1118659CA1Q37816399-368D6A7E-11B3-4975-92E6-160D7F2CC0A9Q37900310-5A638121-3AC5-495E-ACBF-09553C09297AQ38195802-D191680B-EC3B-48B0-941C-00C9F8FF80C1Q40039791-C2E21A86-D48B-4096-91E4-EEE6396DE6DAQ41570433-400B0173-7389-4299-80C1-05B96BA05253Q41608049-542DCF36-4FCC-42CF-BBF0-6B4EA730DD6BQ41897364-9904BE0B-A876-474B-9B80-AC906019D89DQ42772696-56D0B5B2-68C6-4122-A81E-FCE513238244Q44696147-BA3F015B-1209-40CF-9AFD-6192DD7FAF43Q46576615-4C7E5350-CDD0-4940-B75A-DB10B531C3FB
P2860
Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clearance of fungal burden dur ...... tericin B versus itraconazole.
@ast
Clearance of fungal burden dur ...... tericin B versus itraconazole.
@en
type
label
Clearance of fungal burden dur ...... tericin B versus itraconazole.
@ast
Clearance of fungal burden dur ...... tericin B versus itraconazole.
@en
prefLabel
Clearance of fungal burden dur ...... tericin B versus itraconazole.
@ast
Clearance of fungal burden dur ...... tericin B versus itraconazole.
@en
P2093
P1476
Clearance of fungal burden dur ...... tericin B versus itraconazole.
@en
P2093
A Le Monte
AIDS Clinical Trials Group
D E Fuller
Mycoses Study Group of NIAID
P C Johnson
P Connolly
P2860
P304
P356
10.1128/AAC.45.8.2354-2357.2001
P407
P577
2001-08-01T00:00:00Z